Cargando…
NLRC5 inhibits neointima formation following vascular injury and directly interacts with PPARγ
NLR Family CARD Domain Containing 5 (NLRC5), an important immune regulator in innate immunity, is involved in regulating inflammation and antigen presentation. However, the role of NLRC5 in vascular remodeling remains unknown. Here we report the role of NLRC5 on vascular remodeling and provide a bet...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599027/ https://www.ncbi.nlm.nih.gov/pubmed/31253783 http://dx.doi.org/10.1038/s41467-019-10784-y |
_version_ | 1783430876342779904 |
---|---|
author | Luan, Peipei Jian, Weixia Xu, Xu Kou, Wenxin Yu, Qing Hu, Handan Li, Dali Wang, Wei Feinberg, Mark W. Zhuang, Jianhui Xu, Yawei Peng, Wenhui |
author_facet | Luan, Peipei Jian, Weixia Xu, Xu Kou, Wenxin Yu, Qing Hu, Handan Li, Dali Wang, Wei Feinberg, Mark W. Zhuang, Jianhui Xu, Yawei Peng, Wenhui |
author_sort | Luan, Peipei |
collection | PubMed |
description | NLR Family CARD Domain Containing 5 (NLRC5), an important immune regulator in innate immunity, is involved in regulating inflammation and antigen presentation. However, the role of NLRC5 in vascular remodeling remains unknown. Here we report the role of NLRC5 on vascular remodeling and provide a better understanding of its underlying mechanism. Nlrc5 knockout (Nlrc5(−/−)) mice exhibit more severe intimal hyperplasia compared with wild-type mice after carotid ligation. Ex vivo data shows that NLRC5 deficiency leads to increased proliferation and migration of human aortic smooth muscle cells (HASMCs). NLRC5 binds to PPARγ and inhibits HASMC dedifferentiation. NACHT domain of NLRC5 is essential for the interaction with PPARγ and stimulation of PPARγ activity. Pioglitazone significantly rescues excessive intimal hyperplasia in Nlrc5(−/−) mice and attenuates the increased proliferation and dedifferentiation in NLRC5-deficient HASMCs. Our study demonstrates that NLRC5 regulates vascular remodeling by directly inhibiting SMC dysfunction via its interaction with PPARγ. |
format | Online Article Text |
id | pubmed-6599027 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-65990272019-07-01 NLRC5 inhibits neointima formation following vascular injury and directly interacts with PPARγ Luan, Peipei Jian, Weixia Xu, Xu Kou, Wenxin Yu, Qing Hu, Handan Li, Dali Wang, Wei Feinberg, Mark W. Zhuang, Jianhui Xu, Yawei Peng, Wenhui Nat Commun Article NLR Family CARD Domain Containing 5 (NLRC5), an important immune regulator in innate immunity, is involved in regulating inflammation and antigen presentation. However, the role of NLRC5 in vascular remodeling remains unknown. Here we report the role of NLRC5 on vascular remodeling and provide a better understanding of its underlying mechanism. Nlrc5 knockout (Nlrc5(−/−)) mice exhibit more severe intimal hyperplasia compared with wild-type mice after carotid ligation. Ex vivo data shows that NLRC5 deficiency leads to increased proliferation and migration of human aortic smooth muscle cells (HASMCs). NLRC5 binds to PPARγ and inhibits HASMC dedifferentiation. NACHT domain of NLRC5 is essential for the interaction with PPARγ and stimulation of PPARγ activity. Pioglitazone significantly rescues excessive intimal hyperplasia in Nlrc5(−/−) mice and attenuates the increased proliferation and dedifferentiation in NLRC5-deficient HASMCs. Our study demonstrates that NLRC5 regulates vascular remodeling by directly inhibiting SMC dysfunction via its interaction with PPARγ. Nature Publishing Group UK 2019-06-28 /pmc/articles/PMC6599027/ /pubmed/31253783 http://dx.doi.org/10.1038/s41467-019-10784-y Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Luan, Peipei Jian, Weixia Xu, Xu Kou, Wenxin Yu, Qing Hu, Handan Li, Dali Wang, Wei Feinberg, Mark W. Zhuang, Jianhui Xu, Yawei Peng, Wenhui NLRC5 inhibits neointima formation following vascular injury and directly interacts with PPARγ |
title | NLRC5 inhibits neointima formation following vascular injury and directly interacts with PPARγ |
title_full | NLRC5 inhibits neointima formation following vascular injury and directly interacts with PPARγ |
title_fullStr | NLRC5 inhibits neointima formation following vascular injury and directly interacts with PPARγ |
title_full_unstemmed | NLRC5 inhibits neointima formation following vascular injury and directly interacts with PPARγ |
title_short | NLRC5 inhibits neointima formation following vascular injury and directly interacts with PPARγ |
title_sort | nlrc5 inhibits neointima formation following vascular injury and directly interacts with pparγ |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599027/ https://www.ncbi.nlm.nih.gov/pubmed/31253783 http://dx.doi.org/10.1038/s41467-019-10784-y |
work_keys_str_mv | AT luanpeipei nlrc5inhibitsneointimaformationfollowingvascularinjuryanddirectlyinteractswithpparg AT jianweixia nlrc5inhibitsneointimaformationfollowingvascularinjuryanddirectlyinteractswithpparg AT xuxu nlrc5inhibitsneointimaformationfollowingvascularinjuryanddirectlyinteractswithpparg AT kouwenxin nlrc5inhibitsneointimaformationfollowingvascularinjuryanddirectlyinteractswithpparg AT yuqing nlrc5inhibitsneointimaformationfollowingvascularinjuryanddirectlyinteractswithpparg AT huhandan nlrc5inhibitsneointimaformationfollowingvascularinjuryanddirectlyinteractswithpparg AT lidali nlrc5inhibitsneointimaformationfollowingvascularinjuryanddirectlyinteractswithpparg AT wangwei nlrc5inhibitsneointimaformationfollowingvascularinjuryanddirectlyinteractswithpparg AT feinbergmarkw nlrc5inhibitsneointimaformationfollowingvascularinjuryanddirectlyinteractswithpparg AT zhuangjianhui nlrc5inhibitsneointimaformationfollowingvascularinjuryanddirectlyinteractswithpparg AT xuyawei nlrc5inhibitsneointimaformationfollowingvascularinjuryanddirectlyinteractswithpparg AT pengwenhui nlrc5inhibitsneointimaformationfollowingvascularinjuryanddirectlyinteractswithpparg |